We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+38.67%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$144M
AUM Growth
+$17.4M
Cap. Flow
-$19.7M
Cap. Flow %
-13.73%
Top 10 Hldgs %
45.16%
Holding
104
New
9
Increased
14
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.63M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$2.32M
4
ONC
BeOne Medicines Ltd
ONC
+$2.04M
5
ARDX icon
Ardelyx
ARDX
+$1.98M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$4.73M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$4.32M
3
NVAX icon
Novavax
NVAX
+$4M
4
DERM
Dermira, Inc.
DERM
+$3.05M
5
NXTM
NxStage Medical Inc.
NXTM
+$2.75M

Sector Composition

Rank Sector Weight
1 Healthcare 68.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKBA icon
76
Akebia Therapeutics
AKBA
$362M
– –
-24,700
Closed -$185K
AKTX
77
Akari Therapeutics
AKTX
$14M
– –
-1
Closed -$6K
ALDX icon
78
Aldeyra Therapeutics
ALDX
$96.5M
– –
-2,499
Closed -$14K
BPMC
79
DELISTED
Blueprint Medicines
BPMC
– –
-10,100
Closed -$205K
MBAI
80
Check-Cap
MBAI
$8.27M
– –
-368
Closed -$123K
CRBP icon
81
Corbus Pharmaceuticals
CRBP
$168M
– –
-13,333
Closed -$1.2M
GERN icon
82
Geron
GERN
$860M
– –
-285,000
Closed -$764K
CBIO
83
Crescent Biopharma
CBIO
$555M
– –
-280
Closed -$204K
IBB icon
84
iShares Biotechnology ETF
IBB
$9.52B
– –
-18,000
Closed -$1.54M
INDP icon
85
Indaptus Therapeutics
INDP
$192M
– –
-53
Closed -$549K
NVAX icon
86
Novavax
NVAX
$1.22B
– –
-27,500
Closed -$4M
TENX icon
87
Tenax Therapeutics
TENX
$401M
– –
-2
Closed -$204K
VTGN icon
88
VistaGen Therapeutics
VTGN
$9.89M
– –
-1,563
Closed -$183K
VTVT icon
89
vTv Therapeutics
VTVT
$129M
– –
-1,825
Closed -$423K
TRAW icon
90
Traws Pharma
TRAW
$6.72M
– –
0
– -$1K
VIRX
91
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-2,016
Closed -$232K
MRNS
92
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-22,559
Closed -$115K
ATRS
93
DELISTED
Antares Pharma, Inc.
ATRS
– –
-45,000
Closed -$47K
TTPH
94
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-5,185
Closed -$446K
AVEO
95
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-25,907
Closed -$249K
AKAO
96
DELISTED
Achaogen Inc
AKAO
– –
-314,341
Closed -$1.19M
CASC
97
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-29,167
Closed -$165K
LDRH
98
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
– –
-30,000
Closed -$1.11M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return

DAFNA Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, DAFNA Capital Management held 104 positions worth $144M, up 14% from $126M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $19.7M in Q3 2016, closing 29 positions and reducing 21 holdings. Its most notable exit was AbbVie, an estimated $4.73M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in IVERIC bio, Inc. Common Stock worth $2.15M.

  • DAFNA Capital Management's largest Q3 2016 buy was IVERIC bio, Inc. Common Stock: 46,600 shares worth $2.15M.
  • DAFNA Capital Management added most to Tandem Diabetes Care in Q3 2016, an estimated $3M increase.
  • DAFNA Capital Management's biggest Q3 2016 reduction was Rigel Pharmaceuticals, cutting an estimated $4.32M.
  • DAFNA Capital Management fully exited AbbVie in Q3 2016, selling an estimated $4.73M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $144M portfolio in Q3 2016.
  • DAFNA Capital Management opened 9 new positions and closed 29 in Q3 2016.
  • DAFNA Capital Management's portfolio value rose 14% quarter-over-quarter to $144M.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.